

RGC Ref.: N-HKU 741/11

NSFC Ref. :

*(please insert ref. above)*

**The Research Grants Council of Hong Kong  
NSFC/RGC Joint Research Scheme  
Joint Completion Report**

*(Please attach a copy of the completion report submitted to the NSFC  
by the Mainland researcher)*

**Part A: The Project and Investigator(s)**

**1. Project Title**

From bone marrow stromal cells to Schwann cells – *in vitro* route to specification and utility in re-myelination therapy

**2. Investigator(s) and Academic Department/Units Involved**

|  | Hong Kong Team  | Mainland Team   |
|--|---|---|
| Name of Principal Investigator <i>(with title)</i>     | Prof. Daisy Kwok-Yan SHUM   | Dr. Qiang AO  |
| Post   | Professor   | Associate Professor   |
| Unit / Department / Institution                        | School of Biomedical Sciences, The University of Hong Kong                            | Department of Neurosurgery, Yuquan Hospital, Tsinghua University, Beijing 10049 |
| Contact Information                                    | shumdkhk@hku.hk   | aoqiang@tsinghua.edu.cn   |
| Co-investigator(s) <i>(with title and institution)</i> | Prof. Ying-Shing CHAN<br>(School of Biomedical Sciences, The University of Hong Kong) |   |

**3. Project Duration**

|  | Original    | Revised | Date of RGC/<br>Institution Approval<br><i>( must be quoted)</i> |
|--|-------------|---------|--|
| Project Start date                           | 1 Jan 2012  |         |  |
| Project Completion date                      | 31 Dec 2014 |         |  |
| Duration <i>(in month)</i>                   | 36 months   |         |  |
| Deadline for Submission of Completion Report | 31 Dec 2015 |         |  |

## **Part B: The Completion Report**

### **5. Project Objectives**

#### **5.1 Objectives as per original application**

- 1.* To translate the rat protocol to a human protocol for derivation of fate-committed Schwann cells from bone marrow stromal cells (BMSCs).
- 2.* To test for functions of derived Schwann cells in axonal re-growth and re-myelination with use of a new design of nerve conduit in a rat model of sciatic nerve injury.
- 3.* To identify neuron-associated NRG-1 type III as a key effector that specifies commitment of SCLCs to the Schwann cell fate

5.2 Revised Objectives

Date of approval from the RGC: \_\_\_\_\_

Reasons for the change: \_\_\_\_\_  
\_\_\_\_\_

## 6. Research Outcome

Major findings and research outcome

*(maximum 1 page; please make reference to Part C where necessary)*

### **Mainland contribution: Dr. AO, Qiang and his group**

Dr. Ao Qing and his group focused on the design and production of biocompatible nerve conduits. Chitosan was chosen as the conduit material due to its non-antigenic and biodegradable nature. To fulfill the needs of clinical translation, large mammals (goats) were used as animal model in the work. To demonstrate cell carrying and regeneration promoting capability, chitosan conduits pre-seeded with autologous goat bone marrow stromal cells were implanted to bridge a critical 30-mm gap in the severed sciatic nerve. Behavioral tests, high field functional MRI and electrophysiological examination were applied to evaluate locomotor function, *in vivo* structural regeneration and nerve conductivity. Data were collected for up to one year following the nerve-bridging implant before animals were sacrificed for histological analysis of structural regeneration down to cellular level. Results from chitosan conduit group were compared to i) autologous nerve graft group and ii) no conduit/graft control group. One year after transplantation, animals from both conduit and autologous graft group were able to run and feed ad lib. MRI indicated successful regeneration of the bridged sciatic nerve, although the diameter of regenerated nerve was smaller than that receiving the autologous graft. Electrophysiological tests also revealed no significant difference in conductivity between the conduit group and autologous graft group. In contrast, the no conduit group failed to regenerate. Histological examination revealed significant amount of myelinated fibers in regenerated sciatic nerve of the conduit group. However, nerve fiber bundles of the conduit group were not as well organized as those of the autologous graft group. **See Part C: 8.1 - 8.4.** for research outcomes. In conclusion, chitosan conduit represents a feasible alternative for autologous nerve graft. To further improve regeneration, conduits should be pre-seeded with Schwann cells derived by the HKU team.

**Hong Kong contribution: Professor SHUM, Kwok Yan, Daisy and her group**

Professor Shum and her group focused on three aspects:

- (1) Translation to a **human protocol** for derivation of fate-committed Schwann cells from donor BMSCs was accomplished with (i) the derivation of human sensory neurons in an 8-day program from human iPSC, (ii) the conversion of human BMSCs to SCLCs and (iii) the coculture of the derived human neurons and SCLCs. Human Schwann cells can therefore be produced and purified for storage or for therapeutic applications. **See Part C: 8.5, 8.7; 9.1, 9.4, 9.11, 9.12, 9.14** for research outcomes.
- (2) A “Schwann cell-uniaxially aligned chitosan nanofibre Swiss roll” was engineered as a new design of nerve conduit. This was viable in culture and amenable to guide axonal growth and to myelinate axons that sprouted from seeded neurons. **See Part C: 9.3 and 9.8.**
- (3) Underlying mechanism that provides for the phenotypic stability of human BMSC-derived Schwann cells: Coculture of SCLCs with incipient neurons of rat embryonic DRGs allows contact-dependent signaling via (i) interaction of Notch ligands (expressed on neurons) with Notch-1 receptors (expressed on SCLCs) mediates upregulation of ErbB receptors on SCLCs; (ii) in turn, interaction of ErbB receptors (upregulated expression on SCLCs) with NRG-1 type III (expressed on neurons) effects commitment of SCLCs to the Schwann cell fate. **See Part C: 8.6; 9.2, 9.5, 9.6, 9.7, 9.13.**

Potential for further development of the research and the proposed course of action (*maximum half a page*)

**Towards translational research:**

- Following from **Objective 1**, an application for Research Grant (Ref: 03142536) under the Health and Medical Research Fund (HMRF) of the HK Food and Health Bureau “Towards clinical application of human bone marrow stromal cell-derived Schwann cells for repair and regeneration in nerve injury” was submitted in March 2015 but was not funded out of doubt that iPSC-derived sensory neurons cannot materialize. We expect to re-submit for the Research Grant with confidence backed by a manuscript submission to Stem Cell Translational Medicine on the subject.
- Following from **Objective 2**, we expect tests of the “Schwann cell-fibre Swiss roll” as a nerve conduit in a rat model of sciatic nerve injury will allow close collaboration with our Mainland partner, Dr. Ao, in testing the conduit design in a goat model of nerve injury.
- A spinoff from work under **Objective 3** is the emerging prospect of deriving oligodendrocyte precursor cells from bone marrow stromal cells for use in remyelination therapy. [**See Part C: 9.9, 9.10.**] This will provide preliminary results for another HMRF Grant application on the subject of remyelination therapy.

**7. The Layman’s Summary**

*(describe in layman’s language the nature, significance and value of the research project, in no more than 200 words)*

The phenotypic instability of bone marrow-derived Schwann cell-like cells (SCLCs) is at issue with the intended use of these cells for nerve repair and regeneration following therapeutic transplantation. In this work, we demonstrate that commitment to the Schwann cell fate can be acquired by SCLCs in co-culture with sensory neurons via contact-dependent, Notch- and ErbB-mediated signaling, mimicking the niche within developing dorsal root ganglia. Though access to incipient neurons of developing dorsal root ganglia harvested from human embryos is limiting, here we report our use of a human iPSC line to bypass the translational barrier. By various combinations of small-molecule inhibitors of cellular signaling pathways, we arrived at an 8-day programme that effectively and efficiently fostered differentiation of a human iPSC line into sensory neurons. The human iPSC-derived sensory neurons therefore promise

utilization in the translation to a protocol whereby human bone marrow-derived Schwann cells achieve fate commitment and meet safety requirements for autologous transplantation and re-myelination therapy. In collaboration with our Mainland partner, we continue to engineer novel chitosan-based, Schwann cell-seeded nerve conduits for use in bridging critical gaps in severed nerves so as to improve functional recovery.

### Part C: Research Output

#### **8. Peer-reviewed journal publication(s) arising directly from this research project**

(Please attach a copy of each publication and/or the letter of acceptance if not yet submitted in the previous progress report(s). All listed publications must acknowledge RGC's funding support by quoting the specific grant reference.)

| The Latest Status of Publications |   |              |  | Author(s)<br>( <i>bold the authors belonging to the project teams and denote the corresponding author with an asterisk*</i> ) | Title and Journal/<br>Book<br>( <i>with the volume, pages and other necessary publishing details specified</i> )  | Submitted to RGC<br>( <i>indicate the year ending of the relevant progress report</i> ) | Attached to this report<br>( <i>Yes or No</i> ) | Acknowledged the support of this Joint Research Scheme<br>( <i>Yes or No</i> ) | Accessible from the institutional repository<br>( <i>Yes or No</i> ) |
|-----------------------------------|---|--------------|--|---|---|---|---|--|--|
| Year of publication               | Year of Acceptance<br>( <i>For paper accepted but not yet published</i> ) | Under Review | Under Preparation<br>( <i>optional</i> ) |   |   |   |   |  |  |
| 1.                                | 2012  |              |  | Ma T., Niu Y., Zhao C., Su Z.Q., <b>Ao Q.</b> , Zhang X.F., Zhao N.M., Gong Y.D.*   | Amyloid precursor protein-mediated modulation of capacitive calcium entry. <i>Chin Sci Bull</i> , <b>57</b> : 4552-4559.  | n/a   | Yes   | Yes  |  |
| 2.                                | 2012  |              |  | Wei Y.J., Gong K., Zuo H.C., Zhang X.F., Gong Y.D., <b>Ao Q.</b> *  | ADSCs-Chitosan/silk fibroin hybrid enhances sciatic nerve regeneration in a rat model. <i>Chin J Cell Stem Cell</i> , <b>2</b> : 160-168.   | n/a   | Yes   | Yes  |  |
| 3.                                | 2013  |              |  | Song B., <b>Ao Q.</b> , Niu Y., Shen Q., Zuo H.C., Zhang X.F., Gong Y.D.*   | Amyloid beta-peptide worsens cognitive impairment following cerebral ischemia-reperfusion injury. <i>Neural Regen Res</i> <b>8</b> : 2449-2457.                                     | n/a   | Yes   | Yes  |  |
| 4.                                | 2014  |              |  | Liu H., Chen L, Wang Z., Liu W., Ji L. <b>Ao Q.</b> *   | Control release of growth factors combined with small gap anastomosis promotes sciatic nerve regeneration after transaction in rats. <i>Chin J Neurosurg</i> , <b>24</b> : 339-343. | n/a   | Yes   | Yes  |  |

|    |      |      |  |  |  |     |     |     |  |
|----|------|------|--|--|--|-----|-----|-----|--|
| 5. | 2014 |      |  | Cai S., <u>Chan Y.S.</u> , <u>Shum D.K.Y.*</u>   | Induced pluripotent stem cells and neurological disease models. <i>Acta Physiologica Sinica</i> , 66: 55-66.   | n/a | Yes | Yes |  |
| 6. |      | 2015 |  | Tai E.W.Y., Shea G.K.H., Tsui A.Y.P., Mung A.K.L., Leung K.H.Y., Lam J.H.C., <u>Chan Y.S.*</u> , <u>Shum D.K.Y.*</u> | Juxtacrine signaling via Notch and ErbB receptors in the switch to fate commitment of bone marrow-derived Schwann cells. <i>Glia</i> (submitted)   | n/a | Yes | Yes |  |
| 7. |      | 2015 |  | Cai S., Han L., Ao Q., <u>Chan Y.S.*</u> , <u>Shum D.K.Y.*</u>   | Induced pluripotent stem cell-derived sensory neurons for fate commitment of bone marrow-derived Schwann cells – Utilization in re-myelination therapy. <i>Stem Cells Translational Medicine</i> (submitted) | n/a | Yes | Yes |  |

**9. Recognized international conference(s) in which paper(s) related to this research project was/were delivered** (Please attach a copy of each delivered paper. All listed papers must acknowledge RGC's funding support by quoting the specific grant reference.)

| Month/Year/<br>Place           | Title  | Conference<br>Name  | Submitted<br>to RGC<br>(indicate the<br>year ending<br>of the<br>relevant<br>progress<br>report) | Attached<br>to this<br>report<br>(Yes or<br>No) | Acknowledged the<br>support of<br>this Joint<br>Research<br>Scheme<br>(Yes or<br>No) | Accessible<br>from the<br>institutional<br>repository<br>(Yes or No) |
|--------------------------------|--|---|--|---|--|--|
| 1. 03/2012 Hong<br>Kong        | Characterization of human bone marrow stromal cells following differentiation into Schwann cells.<br><u>Cai S.</u> , <u>Tsui A.Y.</u> , <u>Chan Y.S.</u> , <u>Shum D.K.Y.</u>          | 7 <sup>th</sup> Int'l Symposium on Healthy Aging: Live Well, Age Well | 2013   | Yes   | Yes  |  |
| 2. 10/2012 New<br>Orleans, USA | Notch signaling mediates the switch to fate commitment of bone marrow-derived Schwann cells. <u>Shum D.K.Y.</u> , Tai E.W.Y., Shea G.K.H., Tsui A.Y.P., Leung K.H.Y., <u>Chan Y.S.</u> | Annual Meeting of the Society for Neuroscience (USA)                  | 2013   | Yes   | Yes  |  |

|                                   |   |   |      |     |     |  |
|-----------------------------------|---|---|------|-----|-----|--|
| 3. 03/2013<br>Hong Kong           | Aligned chitosan nanofibers for culturing oriented Schwann cells to guide axonal growth. Tung W.Y., Tam K.W., Chan Y.S., Shum D.K.Y.  | 8 <sup>th</sup> Int'l Symposium on Healthy Aging: How to Age with Finesse | 2013 | Yes | Yes |  |
| 4. 03/2013 Hong Kong              | Derivation of human neural crest stem cells from human induced pluripotent stem cells. Cai S., Tsui A.Y., Chan Y.S., Shum D.K.Y.  | 8 <sup>th</sup> Int'l Symposium on Healthy Aging: How to Age with Finesse | 2013 | Yes | Yes |  |
| 5. 03/2013<br>Hong Kong           | Neuregulin 1 type III in the switch of bone marrow stromal cells to fate-committed Schwann cells. Leung K.H., Tsui A.Y., Shea G.K., Tai E.W., Chan Y.S., Shum D.K.Y.                                | 8 <sup>th</sup> Int'l Symposium on Healthy Aging: How to Age with Finesse | 2013 | Yes | Yes |  |
| 6. 07/2013<br>Berlin,<br>Germany. | Notch signaling in in vitro derivation of Schwann cells from bone marrow stromal cells. Tai E.W.Y., Shea G.H.K., Tsui A.Y.P., Leung K.H.Y., Chan Y.S., Shum D.K.Y.                                  | XI European Meeting on Glial Cells in Health and Disease.                 | 2013 | Yes | Yes |  |
| 7. 07/2013<br>Berlin,<br>Germany  | Roles of neuregulin 1 type III in the ex vivo generation of fate committed Schwann cells from bone marrow stromal cells. Leung K.H.Y., Tsui A.Y.P., Shea G.H.K., Tai E.W.Y., Chan Y.S., Shum D.K.Y. | XI European Meeting on Glial Cells in Health and Disease.                 | 2013 | Yes | Yes |  |
| 8. 07/2013<br>Warwick,<br>U.K.    | Oriented Schwann cell culture on aligned chitosan nanofibres for axon growth guidance. Tung W.T., Tam K.W., Chan Y.S., Shum D.K.Y.  | 11 <sup>th</sup> International Conference on Materials Chemistry          | 2013 | Yes | Yes |  |



|                                 |   |  |     |     |     |  |
|---------------------------------|---|--|-----|-----|-----|--|
| 9. 07/2013<br>Birmingham,<br>UK | Derivation of oligodendrocyte precursor cells from bone marrow stromal cells for remyelination therapy. Tsui Y.P., Li R.S., Lo A.C., <u>Chan Y.S.</u> , <u>Shum D.K.Y.</u>  | 37 <sup>th</sup> Int'l Congress of International Union of Physiological Sciences | n/a | Yes | Yes |  |
| 10. 11/2013 San Diego, USA      | Towards remyelination therapy with oligodendrocyte precursor and Schwann cells derived from bone marrow stromal cells. <u>Shum D.K.Y.</u> , Tsui Y.P., Tai W.Y., <u>Chan Y.S.</u>                                   | Annual Meeting of the Society for Neuroscience (USA)                             | n/a | Yes | Yes |  |
| 11. 08/2014 Kaohsiung, Taiwan   | Derivation of stable Schwann cells from human bone marrow stromal cells. Cai S., <u>Chan Y.S.</u> , <u>Shum D.K.Y.</u>  | 11th Biennial Meeting of Asia-Pacific Society for Neurochemistry                 | n/a | Yes | Yes |  |
| 12. 11/2014 Washington DC, USA  | Directed differentiation of human induced pluripotent stem cell to sensory neurons by combined small molecule inhibitors. Cai S., <u>Chan Y.S.</u> , <u>Shum D.K.Y.</u>   | Annual Meeting of the Society for Neuroscience (USA)                             | n/a | Yes | Yes |  |
| 13. 11/2014 Washington DC, USA  | Juxtacrine signalling via Notch and ErbB receptors in the switch to fate commitment of bone marrow-derived Schwann cells. <u>Shum D.K.Y.</u> , Tai E.W.Y., Shea G.H.K., Tsui A.Y.P., Leung K.H.Y., <u>Chan Y.S.</u> | Annual Meeting of the Society for Neuroscience (USA)                             | n/a | Yes | Yes |  |
| 14. 10/2015 Chicago, USA        | Small molecule approach to direct differentiation of human induced pluripotent stem cells to sensory neurons. <u>Shum D.K.Y.</u> , Cai S., Han L., <u>Chan Y.S.</u>   | Annual Meeting of the Society for Neuroscience (USA)                             | n/a | Yes | Yes |  |

**10. Student(s) trained** *(Please attach a copy of the title page of the thesis.)*

| Name                       | Degree registered for | Date of registration | Date of thesis submission/ graduation |
|----------------------------|-----------------------|----------------------|---------------------------------------|
| 1. TSUI, Yat Ping          | PhD                   | September 1, 2010    | Thesis submitted in July 2013         |
| 2. LEUNG, Katherine Ho Yan | MPhil                 | September 1, 2011    | Thesis submitted in August 2013       |
| 3. TUNG, Wing Tai          | MPhil                 | September 1, 2011    | Thesis submitted in February 2014     |
| 4. CHEN, Lin               | PhD                   | September 1, 2010    | Thesis submitted in August 2014       |
| 5. TAI, Evelyn Wing Yin    | PhD                   | September 1, 2010    | Thesis submitted in November 2014     |

**11. Other impact** *(e.g. award of patents or prizes, collaboration with other research institutions, technology transfer, etc.)*

Nil.